Answer
Loncastuximab tesirine (Zynlonta) can cause serious or severe myelosuppression, including neutropenia, thrombocytopenia and anaemia; complete blood cell counts should be monitored before each dose.
Sources for this answer
- Zynlonta, 10mg, powder for concentrate for solution for infusionSwedish Orphan Biovitrum Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 6Document updated
Sources checked